

BRIAN DAVID LAMOREAUX

FACULTY POSITIONS

Horizon Therapeutics

Medical Director, Rheumatology March 2018 – present

Associate Medical Director, Rheumatology July 2016 – February 2018

POST GRADUATE TRAINING

Ohio State University Wexner Medical Center, Columbus, Ohio July 2015 – June 2016
Rheumatology Research Fellow, Clinical Instructor Housestaff

Ohio State University Wexner Medical Center, Columbus, Ohio July 2013 – June 2015
Rheumatology Fellowship, Chief Fellow 2014-15

Medical College of Wisconsin Affiliated Hospitals, Milwaukee, Wisconsin July 2010 – June 2013
Internal Medicine Residency Program, Categorical

EDUCATION

The Ohio State University, Columbus OH September 2014 – May 2016
Master's of Medical Science

Wayne State University School of Medicine, Detroit, MI August 2006 – June 2010
Doctor of Medicine

Michigan State University, East Lansing, MI August 2004 – May 2006
Graduate Epidemiology

Michigan State University, East Lansing, MI August 2000 – May 2004
Bachelors of Science, Psychology, with honors

LICENSURE AND CERTIFICATIONS

Illinois, Medical License (036145749), active 2018 –present

Illinois Physician Controlled Substance License, active 2018 – present

Ohio, Medical license (35.126058), active 2015 – present

Wisconsin, Medical License (56915-20), inactive 2012 – 2014

Drug Enforcement Administration (DEA), active, number available on request 2015 – present

Internal Medicine Board Certification August 2013

Rheumatology Board Certification December 2015

PEER-REVIEWED PUBLICATIONS

Li, J.W., Suh, M., Brigham, M.D., Kent, J.D., **LaMoreaux, B.**, Johnson, R.J., Mandell, B.F., Hadker, N., Sanchez, H., Francis, K., Miyasato, G., “A retrospective study of the effect of gout on mortality among patients with a history of kidney transplantation”, *Annals of Transplantation*, 2020, in press

Brigham, M., Milgroom, A., Lenco, M., Wang, Z., Kent, J., **LaMoreaux, B.**, Johnson, R., Mandell, B.F., Hadker, N., Sanchez, H., Francis, K., Radeck, L., Li, J., “Immunosuppressant use and gout in the prevalent solid organ transplant population”, *Progress in Transplantation*, 2020, in press

Majjhoo, A., Kumar, A., Zdanis, M., **LaMoreaux, B.**, “Comparison of two corticosteroid regimens for pegloticase in the United States: a retrospective analysis in community rheumatology practices”, *Drugs – Real World Outcomes*, 2019, in press

Brigham, M., Milgroom, A., Lenco, M.O., Tudor, T., Kent, J., **LaMoreaux, B.**, Johnson, R., Mandell, B., Hadker, N., Francis, K., Sanchez, H., Radeck, L., Li, J., “Prevalence of gout in the surviving U.S. solid organ transplantation population”, *Transplantation Proceedings*, 2019, in press

Brigham, M., Kent, J., Radeck, L., **LaMoreaux, B.**, Johnson, R., Mandell, B., Mendonca, C., Lang, I., Li, J., “Gout severity in kidney transplant recipients”, *Transplantation Proceedings*, 2019, Jul-Aug;51(6):1816-1821

Keenan, R.T., Baraf, H.S.B., **LaMoreaux, B.**, “Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase”, *Rheumatology and Therapy*, 2019, Mar 14, doi: 10.1007/s49744-0151-9

Lovell, D.J., Dare, J.A., Francis-Sedlak, M., Ball, J., **LaMoreaux, B.**, Von Sheven, E., Reinhardt, A., Jerath, R., Aplan, O., Gupta, R., Goldsmith, D., Zeft, A., Naddaf, H., Gottlieb, B., Jung, L. Holt, R.J., “A 6 month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis”, *Journal of Pediatric Rheumatology*, 2018;16:41

Morton, A., Hosey, A., **LaMoreaux, B.**, “Retreatment with pegloticase after a gap in therapy in patients with gout: a report of four cases”, *Rheumatology and Therapy*, 2018;5(2):583-594

Li, D., Meara, A., **LaMoreaux, B.**, Brock, G., Jarjour, W., “Assessment of cardiovascular disease in rheumatoid arthritis patients”, *Archives of Internal Medicine*, 2017;115-22

LaMoreaux, B., Barbar-Smiley, F., Ardoin, S., Madhoun, H., “Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist”, *Seminars in Arthritis & Rheumatism*, 2015, Feb;45(4):e10-2

Mudd, L.M., Pham, X., Nechuta, S., Elliot, M.R., Lepkowski, J.M., Paneth, N., Michigan Alliance for the National Children’s Study, “Prenatal care and delivery room staff attitudes toward research and the national delivery study”, *Matern Child Health J*, 2008;12:684-691 (in acknowledgements)

PUBLISHED ABSTRACTS and POSTERS

- LaMoreaux, B.**, Francis-Sedlak, M., Holt, R.J., “Incidence gout after renal transplantation in gout-naïve patients: a large database analysis” ACR November 2019
- Albert, J., Hosey, T., **LaMoreaux, B.**, “Subcutaneous or oral methotrexate exposure and response to pegloticase in uncontrolled gout patients in a community rheumatology practice” ACR November 2019
- Francis-Sedlak, M., **LaMoreaux, B.**, Holt, R.J., “Renal transplant complications in patients with and without gout” ACR November 2019
- Mezgebe, M., Francis-Sedlak, M., **LaMoreaux, B.**, Holt, R.J., “Emergency department encounters in a large U.S. payer database: tophaceous versus non-tophaceous gout patients” ACR November 2019
- Li, J.W., Wang, Z., Yin, D., Brigham, M.D., **LaMoreaux, B.**, Kent, J., Francis-Sedlak, M., Johnson, R.J., Hadker, N., Miyasato, G., “Assessing the relationship between gout and return to hemodialysis among renal transplant patients” ACR November 2019
- Marder, B., Khanna, P., **LaMoreaux, B.**, Kumar, A., “Evidence of urate deposition in the kidneys in gout patients” ASN November 2019
- Francis-Sedlak, M., **LaMoreaux, B.**, Holt, R., “Comorbidities in an early diagnosed cohort of uncontrolled versus controlled gout: analysis of a large US payer database” EULAR June 2019
- LaMoreaux, B.**, Francis-Sedlak, M., Holt, R., “Analysis of the prevalence and timing of gout co-morbidity in patients undergoing kidney transplant” EULAR June 2019
- Li, J., Suh, M., Sanchez, H., Kent, J., **LaMoreaux, B.**, Johnson, R., “Impact of gout on all-cause mortality among medicare beneficiaries with a history of kidney transplantation: a retrospective cohort study” EULAR June 2019
- LaMoreaux, B.**, Chandrasekaran, V., “Gout causing cardiac vegetations: summary of published cases” EULAR June 2019
- Mezgebe, M., Francis-Sedlak, M., **LaMoreaux, B.**, Holt, R., “Analysis of comorbidities and hospitalizations in tophaceous and non-tophaceous gout patients in a large US payer database” CCR May 2019
- LaMoreaux, B.**, Francis-Sedlak, M., Holt, R., “Increased cost burden in an early diagnosed cohort of uncontrolled versus controlled gout: analysis of a large US payer database” ACR October 2018
- Brigham, M., Tudor, T., Miyasato, G., Kent, J., **LaMoreaux, B.**, Johnson, R., ACR October 2018

“Prevalence of gout in the surviving U.S. solid organ transplant population”

Milgroom, A., Lenco, M., Francis, K., Kent, J., **LaMoreaux, B.**, Johnson, R., “Immunosuppressant use and gout in the prevalent solid organ transplant population” ACR October 2018

Li, J., Suh, M., Sanchez, H., Kent, J., **LaMoreaux, B.**, Johnson, R., “Early evidence of the association between gout and higher mortality rates in the prevalent solid organ transplant population” ASN October 2018

Radeck, L., Mendonca, C., Lang, I., Kent, J., **LaMoreaux, B.**, Johnson, R., “Gout severity in kidney transplant recipients” ASN October 2018

Mandel, D.R., **LaMoreaux, B.**, “The use of intravenous pegloticase in patients with severe gout arthritis” NEOAPM October 2018

Lovell, D.J., Dare, J.A., Ball, J., Francis-Sedlak, M., **LaMoreaux, B.**, Holt, R.J., “A 6 month, multicenter, open-label, exploratory study of fixed dose naproxen/esomeprazole in adolescent patients with Juvenile Idiopathic Arthritis (JIA)” EULAR June 2018

Schlesinger, N., Khanna, P., **LaMoreaux, B.**, A. Yeo, P. Lipsky, “Evidence based development of criteria for complete response in patients with chronic refractory gout” CCR May 2018

Mandell, B., Baraf, H., **LaMoreaux, B.**, A. Yeo, P. Lipsky, “Rapid tophus resolution in chronic refractory gout patients treated with pegloticase” CCR May 2018

Baraf, H., Morton, A., **LaMoreaux, B.**, Kent, J., “Pegloticase re-treatment after a gap in therapy: data from two phase III trials and an open-label extension study” EULAR June 2017

LaMoreaux, B., “Correlation of erythrocyte sedimentation rate with glycohemoglobin values and other patient factors” ACR November 2016

LaMoreaux, B., Meara, A., Jarjour W., “Control of modifiable cardiovascular risk factors in rheumatoid arthritis patients compared to traditional high-risk cardiovascular disease patients” ACR November 2015

Madhoun, H., **LaMoreaux, B.**, Jarjour, W., et al, “Determining risk factors that increase hospitalizations in patients with systemic lupus erythematosus” ACR November 2014

Fisher, K., Meara, A., Rossetti, A., **LaMoreaux, B.**, et al, “Improving resident confidence with the musculoskeletal exam through a rheumatology dedicated musculoskeletal workshop” ACR November 2014

LaMoreaux, B., Dhakal, B, Pfeifer, KJ. “Raynaud’s to renal crisis: ACP September 2012

an atypical scleroderma presentation”.

LaMoreaux, B, Pfeifer KJ. “Severe hypernatremia and normal saline: tonicity versus textbooks”. ACP September 2012

SELECTED PRESENTATIONS

Horizon 2020 National Sales Meeting, Las Vegas NV February 11th, 2020
“Immunomodulation vs immunosuppression”
“Expert panel discussion: immunomodulation with pegloticase”, moderator

Nephrology Advisory Boards, scientific presenter and co-moderator
“Changing perceptions on the systemic nature of gout”
“Mitigating antibody response to pegloticase”
Los Angeles, CA February 26th, 2020
Chicago, IL February 21st, 2020
Newark, DE January 24th, 2020

Developmental Sciences Ad Board: Subcutaneous pegloticase, Rosemont IL January 18th, 2020
“Uncontrolled gout and pegloticase overview”

Nephrology Advisory Board, San Francisco, CA December 13th, 2019
Co-moderator and scientific presenter, “The systemic nature of gout”
and “Mitigating anti-drug antibodies to pegloticase”

Invited presentation, Arthritis Northwest, Spokane, WA November 20th, 2019
“Gout and pegloticase update”

NSAID Advisory Board, Orlando, FL October 24th, 2019
“Horizon’s Inflammation Portfolio”

PROTECT Clinical Trial Investigator’s Meeting, online meetings October 18th, 25th, 2019
“Therapeutic Area and KRYSTEXXA Overview”
(Clin Trials ID: NCT04087720)

Nephrology Speaker Training, Dallas, TX October 12th, 2019
“Horizon R&D Update”, “Branded Nephrology Speaker Deck”,
“Nephrology Disease State Deck”, and moderator

MIRROR RCT Clinical Trial Investigator’s Meeting, Rosemont IL September 20th, 2019
“Pegloticase update” (Clin Trials ID: NCT03994731)

Loma Linda University Rheumatology Grand Rounds, San Bernadino CA September 12th, 2019
“Gout: Myths and Data”

American Association of Kidney Patients (AAKP), Washington DC September 7th, 2019
“Patient perspective on gout”, “Meet the expert roundtable”

Managed Care Advisory Board, Chicago IL “Overview of OA/RA disease management and unmet needs”	August 22 nd , 2019
Horizon Speaker Training for Rheumatologists & Podiatrists, Dallas TX “Gout Overview Update”, “KRYSTEXXA Safety Update”	April 26 th , 2019
The Ohio State University Rheumatology Grand Rounds, Columbus, OH “Gout: Myths and Data”	March 29 th , 2019
Podiatry Insights Advisory Board, Fort Lauderdale, FL “Strategies to mitigate immunogenicity to pegloticase”	March 22 nd , 2019
Meetings to Assess Perceptions of Safety: Pegloticase Advisory Boards Scientific Presenter and Co-Moderator	
Honolulu, HI	August 28 th , 2019
Honolulu, HI	August 27 th , 2019
Saddle Brook, NJ	May 30 th , 2019
Miami, FL	March 8 th , 2019
Tampa, FL	March 7 th , 2019
Nephrology Speaker Training Meeting, Lake Forest IL “Key Data Review”, “Review of Speaker Slide Deck”	February 20 th , 2019
Horizon’s 2019 National Sales Meeting, Las Vegas, NV “Lupus Overview”, “Lupus expert and patient panel”, moderator	February 12 th , 2019
Nephrology Insights National Advisory Board, Rosemont, IL “Understanding the nephrology perspective on pegloticase”	July 20 th , 2018
University of Florida Rheumatology Grand Rounds, Gainesville, FL “Gout update”	June 1 st , 2018
Cleveland Clinic Nephrology Department, Cleveland OH, Invited Speaker “Gout and pegloticase update: renal perspective”	May 25 th , 2018
Pegloticase scientific advisory board, Destin FL Scientific Presenter and Moderator	May 16 th , 2018
Horizon KRYSTEXXA Speaker Training for 70 Rheumatology Speakers, Dallas TX “Gout Overview Update” and “KRYSTEXXA Safety Update”	May 11 th , 2018
Horizon’s 2018 National Sales Meeting, Las Vegas, NV “Corticosteroids and the Hypothalamic Pituitary Axis”	February 14 th , 2018
Health Care Service Corporation (HCSC), BC/BS for IL, MN, OK, TX, NM “Gout and pegloticase: managed care update”	January 31 st , 2018

Coalition of Rheumatologists and Podiatrists (CORPs), Huntington Beach CA "Krystexxa Scientific Update"	November 17 th , 2017
ACR/ARHP Annual Meeting, San Diego, CA Fellows-In-Training Educational Session, Round Table Moderator	November 3 rd , 2017
Northern California Arthritis Monthly Journal Club: Invited Speaker	August 29 th , 2017
11 th Annual North American Young Rheumatology Investigator Forum, Destin FL Roundtable Discussion Career Development: Panelist	April 26 th , 2017
Biotechnology Innovation Organization (BIO), Washington DC Met with elected representatives around key biotech topics	April 5 th , 2017
Gastroprotection for Patients Speaker Education Session, Rosemont IL Osteoarthritis (OA): Background, Prevalence, and Treatment	April 1 st , 2017
Pegloticase scientific advisory board, Fort Lauderdale FL Scientific Presenter and Moderator	December 4 th , 2016
Pharmaceutical Research and Manufacturers of America (PhRMA), DC Met with elected representatives discussing biomedical research in industry	September 21 st , 2016
Ohio State Medical Student Case-Based Rheumatology Review	Monthly 2015-2016
Internal Medicine Grand Rounds, Ohio State University "Clinical Pathological Conference", moderator	February 19 th , 2015
Sjogren's Walkabout, Invited Expert Speaker, Gahanna, OH	May 29 th , 2014
Internal Medicine Grand Rounds, Medical College of Wisconsin "Perspectives on Global Health: Nepal 2013"	June 14 th , 2013

COMMUNITY INVOLVEMENT

CommunityHealth, Free Clinic in Chicago Staff Clinical Rheumatologist, monthly clinics with follow up	8/2018 – present
Mental Health Association of the North Shore, Chicago Board of Directors	8/2018 – present
Lake Forest College, Lake Forest, IL Career Advancement Center Speed Networking 2019 – Professional Horizon Career Paths – Panelist	October 10 th , 2019 March 26 th , 2019
Michigan State Alumni Association – Chicago Spartans, Chicago IL Lincoln Park Community Services Dinner	November 15 th , 2019

Anti-Cruelty Society, a no-kill animal shelter	August 25 th , 2018
Perspectives Math and Science Academy, Chicago	Annual since 2017
Horizon Pharma's Annual Volunteering Day	

CONFERENCES ATTENDED

ACR, American College of Rheumatology Annual Meeting	Yearly 2014-present
EULAR, European League Against Rheumatism	Yearly 2017-present
CCR, Congress of Clinical Rheumatology, Destin FL	Yearly 2016-present
G-CAN: Gout, Hyperuricemia, and Crystal-Associated Disease Network	Yearly 2016-present
RWCS, Rheumatology Winter Clinical Symposium, Maui, HI	Yearly 2017-2019
International Urate Biology Symposium, Boston MA	June 2019
ASN, American Society of Nephrology	Yearly 2018-present
ISEMER: International Society for Musculoskeletal Imaging in Rheumatology	November 2018
TOGETHER conference: Taskforce for the Generation of Evidence to Resolve the Gout Care Guideline Conflict, MGH, Boston MA	April 7 th , 2018
ACR Winter Rheumatology Symposium, Snowmass CO	January 2017
Rheumatology Research Workshop, San Diego CA	June 2015
Harvard's Annual "Advances in Rheumatology" Course, Boston MA	September 2014
First Year Rheumatology Fellows' Conference, University of Pennsylvania	July 2013

FUNDED GRANTS

Immunoscience Fellows Grant, Bristol Myers Squibb	January 2016
<i>Control of Modifiable Cardiovascular Risk Factors in Rheumatoid Arthritis Patients</i>	\$20,000
Ohio State University Internal Investigator's Award	2016
<i>Correlation of Erythrocyte Sedimentation Rate with Glycohemoglobin Values and other Patient Factors (Statistical support)</i>	\$4,000
Columbus Medical Research Foundation	2014
<i>Prevalence of Cytomegalovirus Infection in Lupus Patients</i>	\$10,000

AWARDS

Horizon Pharma: Presidents Club Award Winner: Rising Star Award <i>Inaugural Bestowment</i>	February 2019
Medical College of Wisconsin: Letter of Commendation <i>Recognized by the Resident Evaluation Committee</i>	June 2012
Medical College of Wisconsin: Housestaff Teaching Award <i>As voted by medical students</i>	July 2012

PATENTS

Reducing immunogenicity to pegloticase Provisional patent number 62/798,783 (1/30/2019) Provisional patent number 62/903,567 (9/20/2019) Provisional patent number 62/903,562 (9/20/2019)	1/30/2020
Combination therapies of prednisone and uricase molecules and uses thereof US/11.11.16/ USP201662421079	3/7/2019
Reducing immunogenicity to pegloticase Application Number 62711214, EFS ID 33306224 (Provisional)	Filed 7/27/2018
Reducing immunogenicity to pegloticase Application Number 62711217, EFS ID 33306271 (Provisional)	Filed 7/27/2018
Combination therapies of prednisone and uricase molecules and uses thereof Serial No. PCT/US2017/061126	Filed 11/10/2017

MENTORSHIP

Julienne Hattar, PharmD, Medical Affairs Fellow at Horizon Therapeutics	2019-2020
Anthony Amatucci, PharmD, Regional Medical Director at Horizon Therapeutics – PRC	2019
Meron Mezgebe, PharmD, Medical Affairs Fellow at Horizon Therapeutics	2018-2019

NON-PEER REVIEWED PUBLICATIONS

“COVID-19 information for elementary-age children”, short video	March 31 st , 2020
“Finding an unlikely culprit: Beyond typical renal disease risk factors”, LinkedIn	March 2 nd , 2020
“Concurrent methotrexate and pegloticase as a treatment for uncontrolled gout”, MD Magazine, video/quoted expert	November 12 th , 2019
Brief video poster description: high versus low uric acid level comparisons in gout patients, for RheumNow at EULAR 2019	June 17 th , 2019
“A Disease by Any Other Name”, LinkedIn	May 13 th , 2019
Horizon Physician Dedicates Time to Underserved Communities On Horizon’s company intranet “The Pulse”, subject and quoted	March 29 th , 2019
“It’s Time to End Our Shame About Gout”, LinkedIn	July 12 th , 2018
“7 Exercises to Help Relieve Joint pain”, Quoted Expert, Everyday Health	March 16 th , 2018

SELECTED WORK EXPERIENCE

Clinical Access, Briston Myers Squibb October 2013 – December 2015
Editor / Writer – Rheumatology Topics

Family Medicine Externship, Oakwood Hospital System, Dearborn, MI Summer 2007
Medical Student Extern. Preceptor: Scott Yaekle, M.D.

Michigan Alliance for the National Children’s Study, East Lansing, MI Aug 2005 – July 2006
Project Coordinator
Kent County Pilot Study for the National Children’s Study

Michigan State University Department of Epidemiology, East Lansing, MI 2005 – 2006
Graduate student assistant
Studied menopausal status and breast cancer risk, with Dr. E.Velie.

Huron River Area Credit Union, Ann Arbor, MI September 1998 – January 2004
Bank Teller – on school breaks.

MEMBERSHIPS

American College of Rheumatology 2013 – Present

American College of Physicians June 2012– Present

American Medical Association August 2006 - Present

Wisconsin Medical Society 2010 – 2013